LGALS1 and hepatocellular carcinoma: Taken together, the above-described results suggest that the high expression of galectin-1 in HSCs can promote local immune privilege (most likely by reducing the number of CD3+ T cells and skewing the Th1/Th2 cytokine balance) and tumour development in HCC and that, these effects can be inhibited by miR-22.